Sjögren's syndrome. (January 2022)

• Record Type: Journal Article
• Authors: Dumusc, Alexandre; Rao, Vijay; Bowman, Simon J.
• Is Part Of: Medicine. Volume 50:Number 1(2022)
• Page Start: 55
• Page End: 59
• Publication Date: 2022-01
• Subjects: Assessment -- biologic therapy -- diagnosis -- histology -- MRCP -- pSS -- sicca syndrome -- Sjögren's syndrome -- therapy; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Médecine factuelle -- Périodiques; Medicine; Periodicals; Electronic journals; Electronic journals; 610
• DOI: 10.1016/j.mpmed.2021.10.009
• Languages: English
• ISSNs: 1357-3039

Abstract

Abstract: Sjögren's syndrome is a systemic autoimmune disorder characterized by focal inflammation of the exocrine glands, leading to dry eyes and dry mouth. Two forms of the syndrome have been defined: primary (pSS), in which dysfunction of the exocrine glands occurs in the absence of other autoimmune diseases; and secondary, in which patients suffer additional autoimmune processes, especially connective tissue disorders such as rheumatoid arthritis, systemic lupus erythematosus and scleroderma. About 70% of patients with pSS have anti-Ro and/or anti-La autoantibodies. Hypergammaglobulinaemia is also common, and a proportion of patients have systemic involvement. Better use of symptomatic therapies can make a big difference to patients, and there is also current interest in whether biologic therapies could be effective in treating pSS.